635 related articles for article (PubMed ID: 26477842)
21. Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision.
Frenkel RE; Shapiro H; Stoilov I
Br J Ophthalmol; 2016 Aug; 100(8):1052-7. PubMed ID: 26541435
[TBL] [Abstract][Full Text] [Related]
22. Bimonthly ranibizumab for neovascular age-related macular degeneration.
Cohen SY; Maloberti B; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Grenet T; Quentel G
Ophthalmologica; 2014; 231(2):80-5. PubMed ID: 24356074
[TBL] [Abstract][Full Text] [Related]
23. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study.
Kim JH; Lee TG; Chang YS; Kim CG; Cho SW
Br J Ophthalmol; 2016 Dec; 100(12):1634-1639. PubMed ID: 26951770
[TBL] [Abstract][Full Text] [Related]
24. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT
BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645
[TBL] [Abstract][Full Text] [Related]
25. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.
Hufendiek K; Hufendiek K; Panagakis G; Helbig H; Gamulescu MA
Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448
[TBL] [Abstract][Full Text] [Related]
26. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M
Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
Rush RB; Rush SW; Aragon AV; Ysasaga JE
Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks.
Amarakoon S; Martinez-Ciriano JP; van den Born LI; Baarsma S; Missotten T
Acta Ophthalmol; 2019 Feb; 97(1):107-112. PubMed ID: 30369062
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial.
Kertes PJ; Galic IJ; Greve M; Williams G; Baker J; Lahaie M; Sheidow T
JAMA Ophthalmol; 2020 Mar; 138(3):244-250. PubMed ID: 31917441
[TBL] [Abstract][Full Text] [Related]
30. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
; Chakravarthy U; Harding SP; Rogers CA; Downes SM; Lotery AJ; Wordsworth S; Reeves BC
Ophthalmology; 2012 Jul; 119(7):1399-411. PubMed ID: 22578446
[TBL] [Abstract][Full Text] [Related]
31. Comparison of intravitreal bevacizumab treatment between phakic and pseudophakic neovascular age-related macular degeneration.
Ozkaya A; Alkin Z; Perente I; Yuksel K; Baz O; Alagoz C; Yazici AT; Demirok A
Nepal J Ophthalmol; 2014; 6(2):145-52. PubMed ID: 25680245
[TBL] [Abstract][Full Text] [Related]
32. Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration.
Hatz K; Prünte C
Br J Ophthalmol; 2016 Oct; 100(10):1341-5. PubMed ID: 26755642
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
[TBL] [Abstract][Full Text] [Related]
34. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
[TBL] [Abstract][Full Text] [Related]
35. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
[TBL] [Abstract][Full Text] [Related]
36. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).
Chakravarthy U; Harding SP; Rogers CA; Downes S; Lotery AJ; Dakin HA; Culliford L; Scott LJ; Nash RL; Taylor J; Muldrew A; Sahni J; Wordsworth S; Raftery J; Peto T; Reeves BC
Health Technol Assess; 2015 Oct; 19(78):1-298. PubMed ID: 26445075
[TBL] [Abstract][Full Text] [Related]
37. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
Karasu B; Gunay BO
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
[TBL] [Abstract][Full Text] [Related]
38. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
Tao Y; Jonas JB
Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
Subramanian ML; Ness S; Abedi G; Ahmed E; Daly M; Feinberg E; Bhatia S; Patel P; Nguyen M; Houranieh A
Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
